Lance K. Gordon, Ph.D.
Dr. Gordon is Chief Executive Officer of VaxGen. For additional information, see Management Team. Click here for additional information.
Donald P. Francis, M.D., D.Sc.
Dr. Francis is president of VaxGen and has served as a director since the company’s inception. For additional information, see Management Team. Click here for additional information.
Phillip W. Berman, Ph.D.
Dr. Berman is VaxGen’s Senior Vice President of Research and Development and has served as a board member since October 1997. Click here for additional information.
Stephen C. Francis
Mr. Francis is Vice Chairman of Fischer, Francis, Trees & Watts, Inc., an investment management firm that he co-founded in 1972. He is a member and former Chairman of the Treasury Borrowing Advisory Committee, which advises the U.S. Treasury, and is a former member of the Stanford University Graduate School of Business Advisory Council. Mr. Francis, who joined the VaxGen board in October 1996, is the brother of Don Francis.
Ruth B. Kunath
Ms. Kunath is the Biotechnology Portfolio Manager for Vulcan Ventures, Inc., the investment organization of Paul G. Allen. Vulcan is a shareholder of VaxGen. She has been with Vulcan since 1992, managing public and private biotechnology and emerging health care investments. Prior to Vulcan, she served as Senior Portfolio Manager for the health care sector of Bank of America Capital Management. She has served on VaxGen’s board since September 1999.
William D. Young
Mr. Young is Chairman and CEO of ViroLogic Inc., a biotechnology company with products that guide physicians in the selection of effective antiviral drugs. Mr. Young joined ViroLogic after 19 years with Genentech, Inc., where he served as Chief Operating Officer from 1997 to 1999. He also serves on the boards of directors of IDEC Pharmaceuticals and Enricha Inc. Mr. Young was elected to the National Academy of Engineering in 1993 and received an Honorary Doctor of Engineering from Purdue University in 2000 for his contributions to biotechnology.
Randall L-W. Caudill, Ph.D.
Mr. Caudill is president and founder of Dunsford Hill Capital Partners, a San Francisco-based financial consulting firm serving early stage health care and technology companies. Caudill heads the VaxGen board’s Audit Committee and serves on the Compensation Committee and the Genentech Contract Committee. From 1987 to 1997, Caudill was employed by Prudential Securities, where he established and headed the firm’s San Francisco investment banking practice. He also served as head of Prudential’s Mergers and Acquisitions Department and co-head of the investment bank.